|
C87075/SECURE
Title: A
non-interventional long-term post-marketing registry of
patients treated with Certolizumab Pegol (Cimzia) for
Crohn’s Disease
Diagnosis: Crohn’s Disease
Primary Objective: A
registry study to track safety outcomes of patients who have
taken Cimzia for treatment of Crohn’s disease compared to a
non-Cimzia control population.
Eligibility: Patients
who meet the following criteria will be eligible for
participation:
-
Male and females over the
age of 18 years
-
Medically documented
Crohn’s disease longer than a 3 month duration
-
Patient must be about to
receive treatment with Cimizia as part of a pre-existing
management plan for Crohn’s disease and has already been
receiving treatment with Cimzia less than 6 months
Treatment: A 10 year
registry study that will follow the patient that is being
treated medically for his/her disease. A phone interview
will be conducted every 3 months after enrollment.
If interested, please
contact Jennifer Hudgins
410-494-1846 x134 or
jhudgins@gastro-doc.com
Or fill out the
Application to Participate
|
